Why AstraZeneca Stock Was a Winner Today
Key Points
The pharmaceutical sector mainstay reported good news about its developmental hypertension drug.
It purchased the medicine's maker, CinCor Pharma, in early 2023.
- 10 stocks we like better than AstraZeneca Plc ›
Good news from the laboratory put some zip into AstraZeneca (NASDAQ: AZN) shares on Monday. The veteran pharmaceutical company's shares enjoyed a nearly 3% lift across the trading session as a consequence, a rate that convincingly outpaced the S&P 500 index's 1.5% growth.
Lowering patient, and investor, blood pressure
Early this morning, AstraZeneca shared the results of a phase 3 clinical trial of baxdrostat, its investigational drug for treatment-resistant hypertension (i.e., high blood pressure).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
The company said the treatment met its primary endpoint of demonstrating a notable decline in ambulatory 24-hour average systolic blood pressure. It also demonstrated "statistically significant and clinically meaningful" declines in secondary endpoints. These included reductions in ambulatory nighttime average systolic blood pressure, among other measures.
AstraZeneca's hopes for baxdrostat are high, as in early 2023 it acquired the drug by purchasing its developer -- biotech CinCor Pharma -- in a deal valued at $1.8 billion including potential contingent value payments.
Monster potential
That could turn out to be capital very well spent. AstraZeneca said that currently 1.4 billion people around the world are afflicted by hypertension, and in this country around 50% of such folks do not have their blood pressure under control. If and when the company can bring baxdrostat to market, it would have a very sizable addressable market for the drug indeed.
Should you invest $1,000 in AstraZeneca Plc right now?
Before you buy stock in AstraZeneca Plc, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AstraZeneca Plc wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $595,194!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,153,334!*
Now, it’s worth noting Stock Advisor’s total average return is 1,036% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of November 10, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy.
Recommended Articles
